Carlsmed vs TriSalus Life Sciences
Carlsmed reported revenue of $50 million in fiscal 2025, about the same as TriSalus Life Sciences' $45 million in fiscal 2025. Carlsmed's revenue grew 85.9% in its latest year, and TriSalus Life Sciences' grew 53.4%. Carlsmed had an operating margin of -60.5%, against -59.7% at TriSalus Life Sciences. Free cash flow was −$30 million at Carlsmed and −$19 million at TriSalus Life Sciences.
Side by side
| Carlsmed | TriSalus Life Sciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $50M | $45M |
| Revenue growth | 85.9% | 53.4% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 75.3% | 84.6% |
| Operating margin | −60.5% | −59.7% |
| Net margin | −58.7% | −86.9% |
| Free cash flow | −$30M | −$19M |
| Free cash flow margin | −58.6% | −41.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 249.7% | 49.6% |
| Last close | $17.22 | $2.17 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $2.6 million | bought $3.7 million, sold $137,130 |
| Piotroski F-score | — | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CarlsmedTriSalus Life Sciences
Operating margin
Percent of revenue
CarlsmedTriSalus Life Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CarlsmedTriSalus Life Sciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Carlsmed and TriSalus Life Sciences pages.